TandemAI Secures $25 Million in Seed and Pre-A Funding Led by OrbiMed and Chengwei Capital to Advance AI-Driven Drug Discovery Platform

On December 22, 2021, TandemAI announced that it had secured $25 million in seed and Pre-A funding rounds to advance the development of its proprietary computational platform and expand its wet lab operations.The company will closely integrate high-performance computing platforms with biophysics, medicinal chemistry, and biology laboratories to assist partners in the rapid design and optimization of candidate drug molecules. This round of financing was led by Orbimed and Chengwei Capital.

"An AI and computational platform grounded in rigorous biophysics is further expanding new frontiers in drug molecule discovery," said Dr. Guowei Wang, Senior Managing Director and Partner of OrbiMed, who will also join the company's board of directors. "TandemAI has quickly assembled an outstanding core team to seize new opportunities and build a novel drug discovery engine based on precise quantum mechanics, large-scale experimental data, and AI technologies."

TandemAI Co-Founder and CEO Qi HeSaid: "The investment by Orbimed and Chengwei Capital, two leading venture capital institutions, reflects trust in our corporate strategy, business model, and team." These funds will accelerate our business expansion, and our short-term goal is to attract the best talent for our platform and new drug molecule discovery operations.

The co-founders of TandemAI have extensive experience and an outstanding track record in founding, financing, and developing innovative drug discovery companies. Mr. He Qi has held senior management positions at various institutions for over 20 years, including his recent roles as Co-founder and Chief Operating Officer at HiFiBiO and Co-founder and Chief Financial Officer at Harbour BioMed. Dr. Tang Wei, Chief Operating Officer of TandemAI, previously served as CEO and board member of Shanghai ChemPartner. Before joining ChemPartner, he held several senior research positions at Merck, including Distinguished Senior Investigator.

TandemAI is rapidly establishing state-of-the-art wet labs and high-performance computing clusters.

OrbiMed is a leading healthcare investment firm managing approximately $18 billion in assets. OrbiMed invests globally in the healthcare industry through a series of private equity funds, public equity funds, and royalty/credit funds. OrbiMed's team consists of over 100 professionals located in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other major global markets.

Founded in 1999, Becoming Capital is one of the earliest international venture capital firms to invest in local Chinese enterprises. Adhering to its unique investment philosophy of focusing on a few quality investments, making significant commitments, and discovering and nurturing unicorns, it has created China's first evergreen fund (Evergreen Fund), which boasts substantial capital and a perpetual lifespan.

Over the past 20 years, Becoming Capital has invested in high-end intelligent manufacturing, internet, semiconductors, enterprise services, and healthcare industries, with a total investment exceeding 2 billion US dollars. Becoming Capital has invested in more than 100 technology companies in China, 14 of which have successfully gone public. Currently, Becoming Capital has formed an investment landscape focusing on four major fields: industrial internet, consumer upgrading, high-end intelligent manufacturing, and healthcare. Becoming Capital will continue to revolve around core industry layouts, collaborate with enterprises, and seek win-win outcomes.

TandemAI is a technology company dedicated to reshaping the drug molecule discovery platform. The company combines its proprietary high-performance computing platform, driven by quantum mechanics and artificial intelligence, with large-scale efficient wet labs to provide one-stop solutions. TandemAI is building its networked high-performance computing platform and computing power, accelerating the speed of drug molecule discovery, reducing R&D costs, and offering collaboration opportunities for pharmaceutical companies and the scientific community worldwide.